- Signing of a protocol agreement for the creation of a joint venture in Hong Kong.
- Financing secured for up to $20 million over three years, including $10 million in the first year.
- Phase 3 clinical trial expected to begin in the second half of 2026.
Paris (France) and Cambridge (Massachusetts, United States), 28 January 2026 – 7:30 a.m. CET – Biophytis SA (Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a pioneer in the development of transformative therapies impacting longevity, today announces the signing of a landmark agreement to create a Hong Kong-based joint venture, Biophytis Biopharmaceutical Holding Ltd, designed to accelerate the development and commercialization of BIO101 in sarcopenia in Asian markets.
Stanislas Veillet, CEO of Biophytis, states: “This partnership is a historic step in our international development. It gives Biophytis access to Asian markets where the medical needs related to sarcopenia are most significant, while benefiting from the local expertise and financing capabilities of recognized partners. I am delighted by their commitment to working with us, which demonstrates the therapeutic potential of BIO101 and validates Biophytis’ ability to address the challenges of mobility in the elderly and the aging population.”
